Signe Jensen Selected Research

Rheumatic Diseases (Rheumatism)

1/2010

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Signe Jensen Research Topics

Disease

1	Asthma (Bronchial Asthma) 02/2024
1	Tendinopathy (Tendonitis) 01/2018
1	Pain (Aches) 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2010
1	Rheumatoid Arthritis 01/2010
1	Neoplasms (Cancer) 06/2002

Drug/Important Bio-Agent (IBA)

1	Indicators and Reagents (Reagents)IBA 02/2024
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Adalimumab (Humira)FDA Link 01/2010
1	Etanercept (Enbrel)FDA Link 01/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2010
1	Infliximab (Remicade)FDA Link 01/2010
1	ORALIT (ORS)IBA 01/2010
1	Plasminogen Activators (Plasminogen Activator)IBA 06/2002

Therapy/Procedure

1	Injections 01/2018
1	Therapeutics 06/2002